Duchenne Electronic Health Record Study
a study on Duchenne Muscular Dystrophy Dystrophinopathy Dystrophinopathy Symptomatic Female Carrier
Summary
- Location
- at Sacramento, California and other locations
- Dates
- study startedstudy ends around
Description
Summary
This study aims to collect retrospective and prospective, long-term data of patients with dystrophinopathy (including Duchenne, Becker, and female carriers) through electronic transfer. At select clinics across the United States, electronic health record (EHR) data from consented patients will be pushed into PPMD's Duchenne Outcomes Research Interchange (the Interchange), where the EHR data can be combined with patient-reported data from The Duchenne Registry. By combining this data in a central hub, we will gain a more complete picture of Duchenne and Becker muscular dystrophy, allowing researchers and clinicians to develop treatments faster and to improve and refine the standards of care for Duchenne and Becker. The ultimate goal is to optimize function, quality of life, and survival of Duchenne and Becker patients.
EHR data collected will be fully identifiable retrospective data for core clinical data elements going back ten years (as available) from the date of consent; going back one year for retrospective clinical notes from the date of consent; and prospectively collecting both core clinical data elements and clinical notes. Information collected will align with the FHIR U.S. core data elements, also known as the Common Clinical Data Set.
PPMD partnered with Prometheus Research (an IQVIA company), an industry leader in health data informatics, to launch both the EHR Study and the Interchange. All data is stored securely and in accordance with strict industry standards and patient privacy laws. Participation in the EHR data extraction is voluntary, and a patient can withdraw consent at any time.
Official Title
Duchenne Outcomes Research Interchange Data Enrichment Through EHR Extraction
Keywords
Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy, Dystrophinopathy, Dystrophinopathy Symptomatic Female Carrier, Duchenne, Becker, Muscular Dystrophy, Duchenne Muscular Dystrophy, Muscular Dystrophies, Observation
Eligibility
You can join if…
- Duchenne or Becker muscular dystrophy or female carrier
- Must be a patient at an institution that has an established EHR integration set up with PPMD's Interchange
- Must provide consent to have their EHR data pushed to the Interchange and linked to existing Registry data, if applicable
You CAN'T join if...
- Individuals with other forms of muscular dystrophy
- Individuals who do not provide consent
Individuals with Duchenne/Becker who have severe mobility/strength issues need to provide consent and participate with assistance from a caregiver. Adults with communication impairments and/or intellectual disabilities (considered the "decisionally impaired" group for purposes of this study) will be able to consent with the assistance of the adults who are designated Legally Authorized Representative (LAR). Without assistance, this group will be excluded from participation because the consent process.
Locations
- UC Davis Health
accepting new patients
Sacramento California 95817 United States - Primary Children's Hospital
accepting new patients
Salt Lake City Utah 84113 United States - University of Utah Health
accepting new patients
Salt Lake City Utah 84132 United States
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- The Duchenne Registry
- Links
- EHR Study FAQs on The Duchenne Registry website PPMD News article announcing the first patient consented into EHR Study
- ID
- NCT07609394
- Study Type
- Observational [Patient Registry]
- Participants
- Expecting 2500 study participants
- Last Updated
Please contact me about this study
We will not share your information with anyone other than the team in charge of this study, which might include an external sponsor. Providing your contact details does not obligate you to participate in the research.
Thank you!
The study team should get back to you in a few business days.